GRB-7 Facilitates HER-2/Neu-mediated Signal Transduction and Tumor Formation
Overview
Authors
Affiliations
Growth factor receptor-bound protein-7 (GRB-7), an adaptor molecule, can interact with multiple signal transduction molecules. GRB-7 is amplified concurrently with HER-2/Neu in most, if not all, of breast cancer with chromosome 17q11-21 amplification. GRB-7 gene amplification is associated with RNA over-expression. We show GRB-7 protein is over-expressed by immunoblotting in breast cancer cell lines and primary breast tumors with HER-2/Neu protein over-expression. Over-expression of GRB-7 in MCF-7 breast cancer cells that over-express HER-2/Neu leads to activation of tyrosine phosphorylation of HER-2/Neu. Knockdown of GRB-7 expression in SKBR-3 breast cancer cells with naturally occurring HER-2/Neu gene amplification decreases tyrosine phosphorylation of HER-2/Neu. Activation of HER-2/Neu phosphorylation is associated with increase in tyrosine phosphorylation of phosphoinositide-specific lipase C-gamma-1 (PLC-gamma-1) and recruitment of PLC-gamma-1 to HER-2/Neu protein molecule. Activation of downstream protein kinase C (PKC) pathway is evidenced by increase in the phosphorylation of a common PKC substrate-myristoylated alanine-rich protein kinase C substrate (MARCKS). In addition, over-expression of GRB-7 in MCF-7 breast cancer cells that over-express HER-2/Neu leads to activation of AKT phosphorylation. Knockdown of GRB-7 expression in MB-453 and SKBR-3 breast cancer cells results in decrease in AKT phosphorylation. GRB-7 over-expression therefore facilitates activation of phosphorylation of HER-2/Neu and AKT in breast cancer cells with HER-2/Neu over-expression. GRB-7 over-expression in MCF-7 cells over-expressing HER-2/Neu leads to morphologic change of cells and promotes tumor xenograft growth in nude mice. GRB-7 over-expression therefore plays pivotal roles in activating signal transduction and promoting tumor growth in breast cancer cells with chromosome 17q11-21 amplification.
Proteogenomic analysis dissects early-onset breast cancer patients with prognostic relevance.
Yoon K, Kim Y, Jung S, Ryu J, Kim K, Lee E Exp Mol Med. 2024; 56(11):2382-2394.
PMID: 39482530 PMC: 11612404. DOI: 10.1038/s12276-024-01332-w.
Rojhannezhad M, Soltani B, Vasei M, Ghorbanmehr N, Mowla S Sci Rep. 2023; 13(1):19516.
PMID: 37945744 PMC: 10636096. DOI: 10.1038/s41598-023-46460-x.
Bergamini C, Vischioni C, Aguiari G, Grandi C, Terrazzan A, Volinia S Noncoding RNA. 2021; 7(3).
PMID: 34449674 PMC: 8395837. DOI: 10.3390/ncrna7030049.
Vermehren-Schmaedick A, Mhawech-Fauceglia P, Park B, Pejovic T, Luoh S Oncotarget. 2020; 11(24):2273-2289.
PMID: 32595827 PMC: 7299530. DOI: 10.18632/oncotarget.27593.
Sang J, Kulkarni K, Watson G, Ma X, Craik D, Henriques S Molecules. 2019; 24(20).
PMID: 31627265 PMC: 6832895. DOI: 10.3390/molecules24203739.